Search company, investor...

Stage

Series A | Alive

Total Raised

$5M

Last Raised

$5M | 14 yrs ago

About Terapio

Terapio is a company focused on providing natural pain relief solutions within the personal healthcare sector. Their main offerings include TENS machines that deliver electrical impulses to reduce pain and relax muscles, as well as featuring modes for muscle stimulation and massage. The company primarily sells to individuals seeking non-pharmacological pain management options. It is based in Austin, Texas.

Headquarters Location

Austin, Texas, 73301,

United States

Loading...

Loading...

Terapio Patents

Terapio has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/17/2014

5/16/2017

Gastrointestinal tract disorders, Rare diseases, Oral mucosal pathology, Inflammations, Conditions of the mucous membranes

Grant

Application Date

9/17/2014

Grant Date

5/16/2017

Title

Related Topics

Gastrointestinal tract disorders, Rare diseases, Oral mucosal pathology, Inflammations, Conditions of the mucous membranes

Status

Grant

Latest Terapio News

Austin Technology Incubator Graduates Two Bioscience Companies: Savara Pharmaceuticals and Terapio

Jan 26, 2012

Incubator’s Expertise in Bioscience Grows, Graduates Focus on Biopharmaceuticals Austin, Texas (PRWEB) January 26, 2012 Tonight, at a special graduation and alumni event, the Austin Technology Incubator (ATI), a not-for-profit part of the IC2 Institute of The University of Texas at Austin (UT), will graduate 21 companies. Of those 21, two companies were part of ATI’s Bioscience portfolio: Savara Pharmaceuticals and Terapio. Both have had a tremendous impact on the growing bioscience community in Austin, hiring dozens of workers and raising millions of dollars in funding. Over 20+ years, ATI has developed and refined industry specific capabilities, currently organized into Information Technology, Wireless, Clean Energy and Bioscience sectors. In each industry sector, ATI brings its portfolio companies deep domain expertise, market- and technology-specific networks of advisors and investors. Tonight’s graduation event showcases successes in all four sectors, including two remarkable companies in bioscience. Founded in 2008 in partnership with the City of Austin, ATI-Bioscience works closely with other members of the Central Texas and statewide life science ecosystem, including BioAustin, Central Texas Life Science entrepreneurs, the University of Texas faculty and students and regional hospital and healthcare groups. ATI-Bioscience recently completed a study, supported by the regional community and the Economic Development Administration, to quantitate the need of wet-laboratory space to support life sciences companies in Central Texas. ATI-Bioscience has also partnered with UT’s College of Pharmacy to create an on-campus wet lab facility, UTech Dorm Room, which can be accessed by early-stage life sciences companies in Austin. The ATI-Bioscience hosts symBIOsis, a quarterly educational series, co-sponsored with the Rice Alliance, to bring the entrepreneurial, commercial and academic life sciences communities together. The two Bioscience graduates are: Savara Pharmaceuticals is developing the first inhaled antibiotic for cystic fibrosis (CF) patients targeting the highly contagious "super bug❠Methicillin-Resistant Staphylococcus aureus (MRSA). MRSA is dramatically increasing worldwide. Savara’s Aerovanc has recently completed its first clinical with encouraging results. Terapio is a biopharmaceutical company developing the RLIP76 protein as a medical countermeasure for radiation exposure and chemical threats to civilian, military and first responder populations. The RLIP76 protein works though the oxidative stress pathway and protects as both a prophylactic and post-exposure treatment. Terapio tapped the unique talents and network at ATI to help secure Texas ETF, federal grant and venture capital funding totaling over $7M in less than two years. "We are extremely excited and pleased about our first bioscience graduate companies,❠said Cindy WalkerPeach, PhD, Bioscience Director. "Terapio and Savara are exceptional healthcare-focused companies that will not only have a positive impact on patient care but will favorably impact regional economic growth as well.❠About ATI: The Austin Technology Incubator is a not-for-profit part of the IC2 Institute of The University of Texas at Austin that harnesses business, government and academic resources to provide strategic counsel, operational guidance and infrastructure support to its member companies to help them transition from early stage ventures to successful technology businesses. Since its founding in 1989, ATI has worked with hundreds of companies, helping raise close to $1 Billion in investor capital and creating thousands of jobs in Central Texas. For more information, visit http://www.ati.utexas.edu. Contact: Laura Beck for ATI laurabeckcahoon(at)gmail(dot)com 512-786-1098 ### For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/1/prweb9136575.htm This article (Austin Technology Incubator Graduates Two Bioscience Companies: Savara Pharmaceuticals and Terapio) was originally developed by and is property of American Banking News. Checkout American Banking News for up-to-date banking news and peer to peer lending news.

Terapio Frequently Asked Questions (FAQ)

  • Where is Terapio's headquarters?

    Terapio's headquarters is located at Austin.

  • What is Terapio's latest funding round?

    Terapio's latest funding round is Series A.

  • How much did Terapio raise?

    Terapio raised a total of $5M.

  • Who are the investors of Terapio?

    Investors of Terapio include Sante.

  • Who are Terapio's competitors?

    Competitors of Terapio include Horizon Therapeutics, Arena Pharmaceuticals, Adamas Pharmaceuticals, Eiger BioPharmaceuticals, Pulmatrix and 7 more.

Loading...

Compare Terapio to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company focused on the discovery and clinical development of proprietary drugs for inflammatory, liver, and metabolic diseases. The company's main offerings include oral drugs that target the A3 adenosine receptor to modulate inflammatory and cancer pathways, with a pipeline of drug candidates in Phase II and Phase III clinical trials. Can-Fite's products are designed to have anti-inflammatory and anti-cancer effects by binding to the A3AR and affecting the NF-kB and Wnt signal transduction pathways. It is based in Petach-Tikva, Israel.

M
MAKScientific

MAKScientific is a pharmaceutical company focused on developing medications for metabolic disorders, pain, addiction, and neurological diseases by targeting the endocannabinoid system. The company's main offerings include a pipeline of small molecule modulators designed to selectively interact with components of the endocannabinoid system, such as cannabinoid receptors and enzymes. MAKScientific's advanced drug candidate, AM6545, is a peripherally restricted CB1 receptor antagonist intended for the treatment of chronic liver disease and metabolic disorders. It is based in Westmystic, Connecticut.

T
Tacere Therapeutics

Tacere Therapeutics is a biotechnology company focused on the development of novel therapeutics for serious infectious diseases. The company specializes in RNA interference (RNAi) technology to create treatments that target and silence specific genes associated with the progression of diseases such as Hepatitis C (HCV). It was founded in 2006 and is based in San Jose, California.

V
Verva Pharmaceuticals

Verva Pharmaceuticals is an exciting, clinical-stage pharmaceutical company focused on the discovery and development of therapies to treat metabolic diseases (formerly Adipogen).

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.